21. Mitochondrial disease Clinical trials / Disease details
Clinical trials : 39 / Drugs : 42 - (DrugBank : 32) / Drug target genes : 47 - Drug target pathways : 67
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05241262 (ClinicalTrials.gov) | December 1, 2022 | 3/2/2022 | Study of N-acetylcysteine in the Treatment of Patients With the m.3243A>G Mutation and Low Brain Glutathione Levels | A Multiple Ascending Phase 1 Dose Study of N-acetylcysteine in the Treatment of Patients With the m.3243A>G Mutation and Low Brain Glutathione Levels | Mitochondrial Disease | Drug: N-Acetylcysteine | Darryl C. De Vivo, MD | United States Department of Defense | Recruiting | 18 Years | 80 Years | All | 18 | Phase 1 | United States |